Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2019 / Article

Case Report | Open Access

Volume 2019 |Article ID 4380429 | 4 pages | https://doi.org/10.1155/2019/4380429

A Case of Fusobacterium necrophorum without Lemierre’s Syndrome Mimicking Acute Leptospirosis

Academic Editor: George N. Dalekos
Received16 Jun 2019
Accepted05 Sep 2019
Published22 Sep 2019

Abstract

Jaundice, conjunctival hyperemia, and acute kidney injury (AKI) are the characteristics of leptospirosis. However, it is not well known that Fusobacterium necrophorum infection can have a clinical picture similar to that of leptospirosis. A 38-year-old man was admitted with jaundice, conjunctival hyperemia, and AKI for 7 days. Chest CT scan showed multiple pulmonary nodules, atypical for leptospirosis. We started treatment with IV piperacillin-tazobactam and minocycline. He became anuric and was urgently started on hemodialysis on the second hospital day. Later on, blood cultures grew Fusobacterium necrophorum and other anaerobic bacteria. Antibody and PCR assays for Leptospira were negative. We narrowed the antibiotics to IV ceftriaxone and metronidazole. He responded well to the treatment and was discharged on the 18th hospital day. F. necrophorum infection is known to cause mixed infection with other anaerobic bacteria. The resistance of many anaerobic bacteria continues to progress, and F. necrophorum itself sometimes produces β-lactamase. This case highlights the potential risks of using penicillin before diagnosis of leptospirosis.

1. Introduction

Jaundice, conjunctival hyperemia, and acute kidney injury (AKI) are the characteristics of leptospirosis [1, 2], which can be treated with penicillin [3]. However, Fusobacterium necrophorum infection may mimic leptospirosis [46], which is not well known. F. necrophorum often causes mixed infections with other anaerobic bacteria. In addition, the antimicrobial resistance of anaerobic bacteria is serious, and sometimes F. necrophorum itself also produces β-lactamase [7]. We present a case of F. necrophorum mixed-infection mimicking leptospirosis that might have treatment failure with penicillin.

2. Case Summary

A 38-year-old man presented with a seven-day history of fatigue, fever, and jaundice. He initially went to a nearby clinic as symptoms worsened. Subsequently, he was also diagnosed with AKI and transferred to our hospital. He had no contact with rats and did not do field work. He had no prior medical history.

Vital signs at the time of visit were as follows: blood pressure 116/73 mmHg, pulse 110/min, body temperature 37.4°C, and respiration rate 18/min. His ocular conjunctivae wereyellow-tinged and congested. His oral cavity was not swollen or reddish; however, he complained of a sore throat.

Blood tests revealed a white blood cell count of 18900/μL. His hemoglobin was 10.8 g/dL and platelet count was 2.6 × 104/μL, and no schizocytes were observed. Aspartate aminotransferase was 31 U/L, alanine aminotransferase 18 U/L, lactate dehydrogenase 234 U/L, alkaline phosphatase 340 U/L, γ-glutamyltransferase 41 U/L, total bilirubin 12.4 mg/dL, and direct bilirubin 10.5 mg/dL, which is above the threshold for hyperbilirubinemia. Blood urea nitrogen was 85.6 mg/dL, creatinine was 8.3 mg/dL, and C-reactive protein was elevated to 29.26 mg/dL (normal range 0.0–0.3 mg/dL). In urine qualitative assays, positive results were observed for proteins, urobilinogen, bilirubin, and occult blood. In addition, urine sugar was positive despite not having diabetes. Chest CT showed multiple nodules in both lungs (Figure 1). Abdominal CT showed no abnormality that could explain the jaundice and kidney failure.

We initially strongly suspected leptospirosis. However, other infectious diseases could not be excluded because the multiple nodules in the lungs were atypical for leptospirosis.

Because there was a possibility of various diseases, we avoided IV penicillin and started IV piperacillin-tazobactam and minocycline instead. He became anuric and was started on urgent hemodialysis on the second hospital day. Later on, antibody and PCR assays for Leptospira were negative. F. necrophorum was isolated in blood cultures on the second day. Further late, Streptococcus intermedius were isolated in blood cultures on the seventh day. We diagnosed his main disease as F. necrophorum rather than S. intermedius bacteremia based on the past case reports and the speed of positive blood cultures. Since F. necrophorum is famous for Lemierre’s syndrome, we performed ultrasound in his jugular vein but found no thrombus. In addition, the dentist diagnosed a minor periodontal infection. F. necrophorum is thought to spread from periodontal infections. The main pathogen was F. necrophorum, but other anaerobic bacteria were also suspected to be involved. In addition, we were not able to test the susceptibility of F. necrophorum to penicillin. His treatment was thus de-escalated to IV ceftriaxone (CTRX) 1 g every 24 h and metronidazole (MNZ) 500 mg every 12 h on the 3rd day. Later, MNZ was increased up to 500 mg every 6 h. These treatments were continued up to the 17th day. The multiple lung nodules formed cavities and later disappeared after definitive therapy (Figure 2). He responded well to the treatment, was taken off hemodialysis, and discharged on the 18th hospital day. After discharge, he continued the treatment with amoxicillin and MNZ orally for three weeks (Figure 3). He had no relapse after three months of follow-up.

3. Discussion

This was a case of F. necrophorum infection without Lemierre’s mimicking leptospirosis. Differentiating between these two diseases is important from the viewpoint of early antibacterial drug selection and identification of complications.

Leptospirosis is a zoonosis caused by the pathogenic spirochete Leptospira spp. Its occurrence is distributed throughout the world but is especially frequent in tropical areas [8]. The main vectors are rodents. Leptospira infects humans via contact of the skin, mucous membranes, and conjunctiva with animal urine and contaminated water and soil. After the incubation period, which is usually ten days, fever, muscle pain, and headache appear in 75–100% of patients [9]. When leptospirosis becomes severe, it complicates with symptoms of jaundice and renal failure [1]. That is also known as Weil’s disease. Conjunctival hyperemia has also been observed in 55% of cases and is a symptom useful for differentiation from other infectious diseases [2].

F. necrophorum is an anaerobic Gram-negative bacillus that is resident in the oral cavity [10]. F. necrophorum infection decreased after the spread of penicillin [11]; however, F. necrophorum infection, and especially pharyngitis, has increased in recent years [12]. In addition, F. necrophorum infection has a 5–9% mortality rate even with antibiotics [10].

F. necrophorum infection is sometimes accompanied by jaundice. Especially, most cases of frank jaundice or hyperbilirubinemia due to F. necrophorum infection had a thrombus in the internal jugular vein, which progressed to Lemierre’s syndrome [13]. This is a new point from this case: this case had no thrombus in the internal jugular vein. The exact frequency of jaundice by F. necrophorum is unknown. Moreover, there are completely different reports: frank jaundice is rare [14] or up to 49% [15]. In addition, the exact mechanism of jaundice by F. necrophorum remains unclear. We assume the lipopolysaccharide of F. necrophorum may affect jaundice because hyperbilirubinemia in sepsis is due to cholestasis by the lipopolysaccharide of bacteria [16], and the main toxicity of F. necrophorum is also from its lipopolysaccharide [17]. In addition, hemophagocytic lymphohistiocytosis can also be a differential diagnosis of jaundice and liver damage. In general, diagnosis of hemophagocytic lymphohistiocytosis in adults is due to multiple findings: fever ≥38.5°C, splenomegaly, pancytopenia, hypertriglyceridemia, and hyperferritinemia [18]. In this case, we did not measure triglyceride and ferritin, nor do a bone marrow puncture; therefore, we cannot deny hemophagocytic lymphohistiocytosis completely.

F. necrophorum sometimes has remote infection sites; in particular, septic embolism in the lung is found in 97% of F. necrophorum infections [13]. Septic embolism in the lung is an important feature of F. necrophorum infection and is not usually seen in leptospirosis. As the presence or absence of septic embolism can also affect the treatment period, it is important to differentiate between the two diseases. Incidentally, in this case, septic embolism in the lung was observed, and it was thought to be a disease condition close to Lemierre’s syndrome, which is a severe clinical disease type of F. necrophorum infection characterized by pharyngitis and purulent thrombophlebitis in the jugular vein accompanied with bacteremia. However, thrombophlebitis of the jugular vein was not found by ultrasound or CT scan in this case.

This case showed the potential risks of using penicillin before diagnosis of leptospirosis. Penicillin is common for the treatment of leptospirosis [3]. F. necrophorum infection often causes a mixed infection with other anaerobic bacteria. In fact, our case was a mixed infection with S. intermedius. Antimicrobial resistance of anaerobic bacteria continues to progress; some anaerobic bacteria is resistance to penicillin. In addition, F. necrophorum itself occasionally produce β-lactamase [7]; that is, 2% of F. necrophorum is resistance to penicillin [19]. Unfortunately, we did not test susceptibility of F. necrophorum to PCG. Therefore, it is not exactly known whether this case has failed with penicillin or not; however, it remains a possibility that it may fail in a case of F. necrophorum and mixed infection. F. necrophorum is sensitive to CTRX and β-lactamase inhibitor combination drugs [2], and CTRX is equivalent to the penicillin group in the therapeutic effect against Leptospira [20, 21]. Therefore, initial treatment with cephalosporin or a β-lactamase inhibitor combination drug may be preferred when the cause of an infection has not been or cannot be distinguished.

We experienced a case of F. necrophorum infection mimicking leptospirosis. This case suggests the potential risks of using penicillin before a diagnosis of leptospirosis.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Authors’ Contributions

RY and SS were responsible for writing the manuscript and the literature search. TY was involved in reviewing the manuscript and the literature search.

References

  1. S. Schreier, G. Doungchawee, S. Chadsuthi, D. Triampo, and W. Triampo, “Leptospirosis: current situation and trends of specific laboratory tests,” Expert Review of Clinical Immunology, vol. 9, no. 3, pp. 263–280, 2013. View at: Publisher Site | Google Scholar
  2. N. B. Vanasco, M. F. Schmeling, J. Lottersberger, F. Costa, A. I. Ko, and H. D. Tarabla, “Clinical characteristics and risk factors of human leptospirosis in Argentina (1999–2005),” Acta Tropica, vol. 107, no. 3, pp. 255–258, 2008. View at: Publisher Site | Google Scholar
  3. M. D. Baber and R. D. Stuart, “Leptospirosis canicola a case treated with penicillin,” The Lancet, vol. 248, no. 6426, pp. 594–596, 1946. View at: Publisher Site | Google Scholar
  4. D. Lin, N. Suwantarat, and R. S. Young, “Lemierre’s syndrome mimicking leptospirosis,” Hawaii Medical Journal, vol. 69, no. 7, pp. 161–163, 2010. View at: Google Scholar
  5. T. Wingfield, T. J. Blanchard, and K. M. B. Ajdukiewicz, “Severe pneumonia and jaundice in a young man: an atypical presentation of an uncommon disease,” Journal of Medical Microbiology, vol. 60, no. 9, pp. 1391–1394, 2011. View at: Publisher Site | Google Scholar
  6. Y. W. Han, “Fusobacterium nucleatum: a commensal-turned pathogen,” Current Opinion in Microbiology, vol. 23, pp. 141–147, 2015. View at: Publisher Site | Google Scholar
  7. S. Ahkee, L. Srinath, M. J. Raff, A. Huang, and J. A. Ramirez, “Lemierre’s syndrome: postanginal sepsis due to anaerobic oropharyngeal infection,” Annals of Otology, Rhinology & Laryngology, vol. 103, no. 3, pp. 208–210, 1994. View at: Publisher Site | Google Scholar
  8. R. A. Hartskeerl, M. Collares-Pereira, and W. A. Ellis, “Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world,” Clinical Microbiology and Infection, vol. 17, no. 4, pp. 494–501, 2011. View at: Publisher Site | Google Scholar
  9. A. R. Katz, V. E. Ansdell, P. V. Effler, C. R. Middleton, and D. M. Sasaki, “Assessment of the clinical presentation and treatment of 353 cases of laboratory-confirmed leptospirosis in Hawaii, 1974–1998,” Clinical Infectious Diseases, vol. 33, no. 11, pp. 1834–1841, 2001. View at: Publisher Site | Google Scholar
  10. T. Riordan, “Human infection with Fusobacterium necrophorum (necrobacillosis), with a focus on Lemierre’s syndrome,” Clinical Microbiology Reviews, vol. 20, no. 4, pp. 622–659, 2007. View at: Publisher Site | Google Scholar
  11. C. L. Weesner and J. E. Cisek, “Lemierre syndrome: the forgotten disease,” Annals of Emergency Medicine, vol. 22, no. 2, pp. 256–258, 1993. View at: Publisher Site | Google Scholar
  12. R. M. Centor, “Expand the pharyngitis paradigm for adolescents and young adults,” Annals of Internal Medicine, vol. 151, no. 11, pp. 812–815, 2009. View at: Publisher Site | Google Scholar
  13. C. P. Sinave, G. J. Hardy, and P. W. Fardy, “The Lemierre syndrome: suppurative thrombophlebitis of the internal jugular vein secondary to oropharyngeal infection,” Medicine, vol. 68, no. 2, pp. 85–94, 1989. View at: Publisher Site | Google Scholar
  14. J. A. Chirinos, D. M. Lichtstein, J. Garcia, and L. J. Tamariz, “The evolution of Lemierre syndrome: report of 2 cases and review of the literature,” Medicine, vol. 81, no. 6, pp. 458–465, 2002. View at: Publisher Site | Google Scholar
  15. C. M. Leugers and R. Clover, “Lemierre syndrome: postanginal sepsis,” The Journal of the American Board of Family Practice, vol. 8, no. 5, pp. 384–391, 1995. View at: Google Scholar
  16. N. Chand and A. J. Sanyal, “Sepsis-induced cholestasis,” Hepatology, vol. 45, no. 1, pp. 230–241, 2007. View at: Publisher Site | Google Scholar
  17. J. S. Brazier, “Human infections with Fusobacterium necrophorum,” Anaerobe, vol. 12, no. 4, pp. 165–172, 2006. View at: Publisher Site | Google Scholar
  18. M. B. Jordan, C. E. Allen, S. Weitzman, A. H. Filipovich, and K. L. McClain, “How I treat hemophagocytic lymphohistiocytosis,” Blood, vol. 118, no. 15, pp. 4041–4052, 2011. View at: Publisher Site | Google Scholar
  19. J. S. Brazier, B. I. Duerden, E. Yusuf, and V. Hall, “Fusobacterium necrophorum infections in England and Wales 1990-2000,” Journal of Medical Microbiology, vol. 51, no. 3, pp. 269–272, 2002. View at: Publisher Site | Google Scholar
  20. T. Panaphut, S. Domrongkitchaiporn, A. Vibhagool, B. Thinkamrop, and W. Susaengrat, “Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis,” Clinical Infectious Diseases, vol. 36, no. 12, pp. 1507–1513, 2003. View at: Publisher Site | Google Scholar
  21. Y. Suputtamongkol, K. Niwattayakul, C. Suttinont et al., “An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis,” Clinical Infectious Diseases, vol. 39, no. 10, pp. 1417–1424, 2004. View at: Publisher Site | Google Scholar

Copyright © 2019 Ryo Yasuhara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

593 Views | 238 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.